^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Astrocytoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
Excerpt:
...- Non-neurofibromatosis type 1 (non-NF1), non-tuberous sclerosis complex (non-TSC) low-grade glioma (LGG) without a BRAFV600E or IDH1 mutation...
Trial ID:
Source:
Title:
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Excerpt:
...- Patients must have non-neurofibromatosis type 1 (non-NF1) low-grade glioma (LGG) without a BRAFV600E mutation as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1 (NCT02402244) and that has...
Trial ID:
More C2 evidence
Source:
Title:
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Excerpt:
...Plasma drug concentrations and pharmacokinetic parameters (Phase I)`Stratum-specific progression-free survival distribution (PFS) (phase II)`Presence or absence of BRAF V600E mutations or BRAF KIAA1549 fusion (phase II)`Progression-free survival (retreatment study)...
Trial ID:
Source:
Title:
AZD6244 in Children With Low-Grade Gliomas
Excerpt:
...- Stratum 1: Patients with progressive, recurrent or refractory pilocytic astrocytoma with pre-trial tumor material available and with a BRAF aberration i.e. BRAF (V600E) mutation and/or BRAF KIAA1549 fusion as determined by IHC and FISH, respectively. ...
Trial ID:
Less C2 evidence
Source:
Title:
Selumetinib in Children with BRAF-Aberrant or Neurofibromatosis type 1-Associated Recurrent, Refractory or Progressive Low-Grade Glioma: a Multi-Center Phase II Trial
Excerpt:
...Stratum 1 included...pilocytic astrocytoma (PA) harboring either one of the two most common BRAF aberrations (KIAA1549-BRAF fusion or the BRAFV600E mutation)...On stratum 1, 9/25 (36%) patients achieved a partial response (PR)...2/7 (28.6%) of the tumors with BRAFV600E....
DOI:
10.10162FS1470-2045(19)30277-3
Trial ID:
